Fushine Pharmaceuticals recently received GRAS approval for its Weiran protein, following a scientific evaluation conducted in accordance with the US FDA's GRAS guidelines. Fushine Pharmaceuticals has officially become one of the few Chinese companies in the synthetic biology field to gain US market access.

Technology-driven, independent innovation and research and development

FuNext protein, developed by Fushine, is a filamentous fungal protein produced by fermentation of Fusarium spp. It is rich in protein and contains all essential amino acids, as well as vitamins, minerals, and other nutrients. It is high in dietary fiber, low in sugar, low in fat, and cholesterol-free, with an amino acid profile that closely matches human needs. This rich nutritional profile allows FuNext protein to play a vital role in applications ranging from "artificial meat" to protein drinks, snacks to health supplements, and even pet food, meeting the diverse needs of diverse consumers. This wide range of applications not only demonstrates the value of FuNext protein but also provides ample room for its future development.

Safety quality, authoritative food certification

In the past year, Fushine has successfully transformed the scientific research results of microbial protein into actual productivity, and successfully passed the four major international authoritative food safety system certifications including ISO22000, BRC, SQF, HACCP, as well as the HALAL international halal food certification.

This time, the Wei Ran protein produced by Fushine successfully passed the GRAS certification, which means that the product has passed the scientific evaluation process and obtained market access permission from the U.S. FDA (U.S. Food and Drug Administration). It can be sold and used as a safe food ingredient in the U.S. market and other international markets that recognize the U.S. GRAS certification. It will be conducive to promoting the rapid development of the company's microbial protein business, promoting the company's international market development, and will have a positive impact on the company's future operations.

R&D results, multi-morphological samples

At present, Fushine has successfully developed two product forms of dry-based protein and wet-based protein, standing out in the field of microbial protein. It has built a 1,200-ton microbial protein production line and put it into normal production. The annual production of 200,000 tons of microbial protein and comprehensive resource utilization project (Phase I) is under construction.

Fushine Wei Ran protein finished product

Fushine's protein terminal product applications

Future prospects, unlimited potential

With the rapid development of the global synthetic biology industry and people's increasing pursuit of healthy diet, Weiran Protein is bound to shine in the future market.The successful US GRAS certification of Fushine's Weiran protein product is of great significance in many ways. Fushine will continue to increase its R&D investment, continuously optimize Weiran protein's production technology and product quality, expand its application areas, and contribute to the innovation and development of the global food industry.